1.70
-0.03(-1.73%)
Currency In USD
| Previous Close | 1.73 |
| Open | 1.73 |
| Day High | 1.73 |
| Day Low | 1.7 |
| 52-Week High | 2.95 |
| 52-Week Low | 0.99 |
| Volume | 197,432 |
| Average Volume | 1.29M |
| Market Cap | 107.54M |
| PE | -1.4 |
| EPS | -1.21 |
| Moving Average 50 Days | 1.65 |
| Moving Average 200 Days | 1.6 |
| Change | -0.03 |
If you invested $1000 in MacroGenics, Inc. (MGNX) 10 years ago, it would be worth $97.09 as of February 21, 2026 at a share price of $1.7. Whereas If you bought $1000 worth of MacroGenics, Inc. (MGNX) shares 5 years ago, it would be worth $88.63 as of February 21, 2026 at a share price of $1.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 9:05 PM GMT
ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
GlobeNewswire Inc.
Nov 12, 2025 9:01 PM GMT
Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of l
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
GlobeNewswire Inc.
Nov 06, 2025 9:30 PM GMT
ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and